Irreversible blockage of opioid receptor types by ester homologs of .beta.-funaltrexamine
- 1 October 1986
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 29 (10) , 1868-1871
- https://doi.org/10.1021/jm00160a013
Abstract
A series of ester homologues 2-5 of the .mu. receptor nonequilibrium antagonist .beta.-funaltrexamine (1, .beta.-FNA) was synthesized. These ligands were of interest in our investigation of the relationship between the structure of the ester function and the ability to irreversibly block .mu. opioid receptors. While all of the ligands were potent reversible agonists in the guinea pig ileum (GPI) and mouse vas deferens (MVD) preparations, most appeared to behave as irreversible antagonists of morphine. The benzyl 5 and phenethyl 6 esters possessed irreversible .mu. antagonist potency that was of similar magnitude to that of .beta.-FNA in the GPI. In the MVD, all esters appeared to irreversibly block the agonist effect of morphine, but one of the compounds irreversibly antagonized [D-Ala2, D-Leu5]enkephalin to a significant degree. [3H]Dihydromorphine displacement studies revealed no relationship between the affinity of the esters 1-6 and the irreversible blockage of .mu. receptors in the GPI or MVD. Possible reasons for the observed structure-activity relationship are discussed.This publication has 6 references indexed in Scilit:
- Importance of carbon 6 chirality in conferring irreversible opioid antagonism to naltrexone-derived affinity labelsJournal of Medicinal Chemistry, 1983
- Alkylation of opioid receptor subtypes by .alpha.-chlornaltrexamine produces concurrent irreversible agonistic and irreversible antagonistic activitiesJournal of Medicinal Chemistry, 1983
- Pharmacological profiles of β-funaltrexamine (β-FNA) and β-chlornaltrexamine (β-CNA) on the mouse vas deferens preparationEuropean Journal of Pharmacology, 1982
- PHARMACOLOGICAL CHARACTERIZATION INVIVO OF THE NOVEL OPIATE, BETA-FUNALTREXAMINE1982
- Chloroxymorphamine, an Opioid Receptor Site-Directed Alkylating Agent Having Narcotic Agonist ActivityScience, 1979
- STIMULANT ACTIONS OF VOLATILE ANAESTHETICS ON SMOOTH MUSCLEBritish Journal of Pharmacology and Chemotherapy, 1964